These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 20110785

  • 1. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC, Pulido EG, Guillén-Ponce C.
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib: from rational design to clinical efficacy.
    Chow LQ, Eckhardt SG.
    J Clin Oncol; 2007 Mar 01; 25(7):884-96. PubMed ID: 17327610
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib.
    Rini BI.
    Expert Opin Pharmacother; 2007 Oct 01; 8(14):2359-69. PubMed ID: 17927489
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 01; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.
    Clin Cancer Res; 2009 May 15; 15(10):3384-95. PubMed ID: 19417025
    [Abstract] [Full Text] [Related]

  • 8. Sunitinib.
    Heng DY, Kollmannsberger C.
    Recent Results Cancer Res; 2010 May 15; 184():71-82. PubMed ID: 20072832
    [Abstract] [Full Text] [Related]

  • 9. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.
    Cancer Res; 2010 Feb 01; 70(3):1053-62. PubMed ID: 20103629
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib in solid tumors.
    Gan HK, Seruga B, Knox JJ.
    Expert Opin Investig Drugs; 2009 Jun 01; 18(6):821-34. PubMed ID: 19453268
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, Shah P, Ellis L, Shen L, Paesante S, Dykema K, Furge K, Teh BT, Netto G, Pili R.
    Mol Cancer Ther; 2010 Jun 01; 9(6):1525-35. PubMed ID: 20501804
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Pharmacology profile of sunitinib malate (Sutent) Capsules) and clinical findings on this drug].
    Tahara M, Shibata A, Yamaguchi S, Hamada Y.
    Nihon Yakurigaku Zasshi; 2009 Apr 01; 133(4):215-26. PubMed ID: 19367024
    [No Abstract] [Full Text] [Related]

  • 17. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
    Polyzos A.
    J Steroid Biochem Mol Biol; 2008 Feb 01; 108(3-5):261-6. PubMed ID: 17945482
    [Abstract] [Full Text] [Related]

  • 18. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors.
    Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, Durante C.
    Oncol Rep; 2011 Nov 01; 26(5):1075-80. PubMed ID: 21850379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
    Papaetis GS, Syrigos KN.
    BioDrugs; 2009 Nov 01; 23(6):377-89. PubMed ID: 19894779
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.